Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5036MR)

This product GTTS-WQ5036MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Heloderma suspectum
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5036MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9469MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ2698MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ96MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ15869MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ11107MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ14300MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ3101MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ1525MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW